June 11, 2021

Improved Survival among Hospitalized Patients with COVID-19 Treated with Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A retrospective cohort study from Denmark found that patients hospitalized with COVID-19 (N=2,747) who were treated with remdesivir and dexamethasone had lower odds of 30-day mortality (OR=0.47) and progression to mechanical ventilation (OR=0.36) compared to persons receiving the standard of care. However, the authors caution that because treatment was not randomized, study data does not permit the distinction between individual effects of the drugs vs. additional interventions during hospitalization on measured outcomes. However, the authors controlled for confounding factors that may have influenced treatment decisions and disease severity by using inverse probability weighted logistic regression. 

Benfield et al. (June 2021). Improved Survival among Hospitalized Patients with COVID-19 Treated with Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab536